Dolutegravir may interact with mineral supplements containing calcium, iron, magnesium, or zinc, reducing its absorption. To avoid this, separate the dosing by at least two hours-take the antiretroviral first, then the multivitamin later.
Dolutegravir does not significantly induce or inhibit the enzymes that metabolise hormonal contraceptives, so it is unlikely to reduce their effectiveness. Nonetheless, discuss all concurrent medicines with your clinician to ensure optimal protection.
No. Dolutegravir can be taken with or without food. A high-fat meal may increase drug exposure modestly, but this does not require dose adjustment.
If you remember the missed dose within 12 hours, take it as soon as possible. If it is close to the time of your next scheduled dose, skip the missed tablet and continue with your regular schedule. Do not double-dose.
Dolutegravir itself is not hepatotoxic, but patients co-infected with hepatitis B or C should have regular liver function monitoring. The drug can be part of a regimen that also treats hepatitis B when combined with appropriate agents.
Clinical observations have noted modest weight increases in some patients, particularly when dolutegravir is paired with tenofovir alafenamide. The mechanism is not fully understood, and the benefit of viral suppression generally outweighs this effect.
Dolutegravir is not typically screened for in standard workplace or sports drug tests. It is not classified as a performance-enhancing or prohibited substance.
Yes. The active ingredient, dolutegravir sodium, is available as a generic medication in the same 50 mg tablet formulation, subject to the same prescribing regulations.
Most patients achieve an undetectable viral load within 8-12 weeks of initiating a fully suppressive regimen that includes dolutegravir, provided adherence is good.
A mild rash is often self-limiting. However, if you notice widespread redness, swelling, blistering, or difficulty breathing, seek immediate medical care as this could represent a serious allergic reaction.
Dolutegravir is an antiretroviral medication used to treat Human Immunodeficiency Virus (HIV) infection.
Dolutegravir is not a cure for HIV but a core component of combination antiretroviral therapy (cART) that suppresses viral replication, helps maintain immune function, and reduces the risk of HIV transmission.
Dolutegravir inhibits the HIV integrase enzyme, which is essential for inserting viral DNA into the host’s genome. By binding to the active site of integrase, the drug prevents the strand-transfer step of integration, halting the establishment of new infection cycles.
Because dolutegravir does not rely heavily on CYP enzymes, it has a relatively low potential for drug-drug interactions compared with many other antiretrovirals.
In the United Kingdom, dolutegravir is approved as part of combination regimens for the following indications:
Dolutegravir is used together with other antiretrovirals (e.g., nucleoside reverse-transcriptase inhibitors like tenofovir disoproxil fumarate/emtricitabine) to build a complete three-drug regimen.
Current peer-reviewed evidence does not support routine off-label use of dolutegravir for conditions outside HIV infection. Investigational studies have explored its role in HIV pre-exposure prophylaxis (PrEP) and in long-acting injectable formulations, but these remain experimental and are not approved by the MHRA.
Disclaimer: Off-label use of any medication must be prescribed and monitored by a qualified HIV specialist, with a clear assessment of benefits and risks.
These events typically improve within the first few weeks of therapy and rarely require discontinuation.
If any of the following occur, seek immediate medical attention: severe rash, signs of liver injury (jaundice, dark urine), or symptoms suggestive of an allergic reaction (swelling of face or throat).
Patients should be instructed to report new neurological symptoms, severe rash, or signs of liver injury promptly.
This article provides educational information about Dolutegravir and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
